ImmunoPrecise Antibodies (IPA)
(Delayed Data from NSDQ)
$1.89 USD
+0.08 (4.42%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $1.89 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Market Cap
As of the previous market close, ImmunoPrecise Antibodies Ltd. has a market cap of $83.54M, which represents its share price of $1.81 multiplied by its outstanding shares number of 46.15M. As a small-cap company, IPA's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
IPA 1.89 +0.08(4.42%)
Will IPA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IPA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IPA
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q4 Loss, Lags Revenue Estimates
ImmunoPrecise Antibodies (IPA) Upgraded to Buy: What Does It Mean for the Stock?
IPA: What are Zacks experts saying now?
Zacks Private Portfolio Services
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Misses Revenue Estimates
P3 Health Partners Inc. (PIII) Reports Q4 Loss, Lags Revenue Estimates
Nyxoah SA (NYXH) Reports Q4 Loss, Lags Revenue Estimates
Other News for IPA
ImmunoPrecise Antibodies divests Netherlands facilities to AVS Bio
ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate ...
AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and ...
ImmunoPrecise Antibodies Ltd (IPA) Q4 2025 Earnings Call Highlights: Record Revenue and ...
ImmunoPrecise Antibodies Ltd. (IPA) Q4 2025 Earnings Conference Call Transcript